Navigation Links
OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
Date:10/17/2007

Latest Randomized Clinical Trial Results of First Pro-Healing Stent Also

Featured at Annual Symposium

HONG KONG, Oct. 18 /PRNewswire/ -- OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is the subject of several sessions about innovation in interventional cardiology strategies and device design at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, which is set for Oct. 20-25 at the Washington Convention Center in Washington, D.C.

The line-up of sessions that feature the first pro-healing stent, which is an alternative to drug-eluting stents, includes:

- Interventional Strategies and Adjunct Pharmacology in ACS and AMI;

Should Specialized DES for AMI be Developed? Early Experience with EPC

Capture Technology; Jan Henk Dambrink, M.D., Ph.D., Department of

Cardiology, ISALA Klinieken, Hospital De Weezenlanden, Zwolle, The

Netherlands; 2:10 p.m. EDT on Oct. 21; Room 151B

- Innovative Devices and Futuristic Concepts: Novel Bare Metal and Drug-

Eluting Stents; The Genous Stent Coating with CD34 Antibodies to

Actively Capture Circulating EPCs: Design Parameters and Effects on

Healing and Thrombogenicity; Michael Kutryk, M.D., clinician scientist

and interventional cardiologist at St. Michael's Hospital, assistant

professor at the University of Toronto; Canada; 3:08 p.m. EDT on Oct.

21; Room 152A

In addition, the latest results from clinical trials of the Genous stent will be discussed by Robbert de Winter, M.D., Ph.D., principal investigator and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. Specifically, de Winter will present:

- Updates from the HEALING studies, AMC "Real World" registry and TRIAS

trial; 4:36 p.m. EDT on Oct. 21; Ballroom C, 3rd floor

- A late-breaking report of six-month clinical outcomes from the TRIAS HR

pilot study: a prospective, randomized trial comparing the Genous stent

and a paclitaxel-eluting stent in lesions at high risk for restenosis;

12:45 p.m. EDT on Oct. 22; Main Arena

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody- coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
5. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
6. Pharmathenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
7. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
8. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
10. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):